Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: pembrolizumab, colorectal cancer, immune checkpoint inhibitors, anti-PD-1 therapy, disease control rate, progression-free survival, overall survival, treatment safety, advanced colorectal cancer, genomic profiling, targeted therapy, biomarker-guided therapy, patient-reported outcomes, quality of life
Open Access status: closed
OpenAlex ID: W2947703016
